机构地区:[1]宁夏医科大学第三临床医学院、宁夏回族自治区人民医院消化内科,银川750002 [2]宁夏回族自治区人民医院宁南医院消化内科,中卫755299 [3]宁夏回族自治区第五人民医院消化内科,石嘴山753099 [4]中卫市人民医院消化内科,中卫755099 [5]吴忠市盐池县人民医院消化内科,吴忠751599 [6]石嘴山市平罗县人民医院消化内科,石嘴山753499
出 处:《中华消化杂志》2024年第5期302-307,共6页Chinese Journal of Digestion
基 金:宁夏回族自治区重点研发计划重大项目(2019BFG02003);宁夏回族自治区重点研发计划(2021BEG02025)。
摘 要:目的探讨宁夏地区克拉霉素敏感性检测指导下精准与经验性含铋剂四联疗法在首次根除幽门螺杆菌(H.pylori)中的疗效。方法选取2022年8月12日至2023年3月22日于宁夏回族自治区人民医院、宁夏回族自治区人民医院宁南医院、中卫市人民医院、吴忠市盐池县人民医院、石嘴山市平罗县人民医院就诊的经14C-尿素呼气试验(14C-UBT)初次诊断为H.pylori阳性患者600例,采用随机数字表法分为经验性治疗组(以下简称经验组)、基因检测组(以下简称基因组)、药敏试验组(以下简称药敏组),每组200例患者。经验组未行药敏试验和基因检测。基因组和药敏组分别经基因检测和药敏试验明确对克拉霉素敏感,并排除耐药患者。3组患者均接受相同克拉霉素含铋剂四联治疗方案,采用意向性治疗集(ITT)和符合方案集(PP)分析比较3组的H.pylori根除率。基于ITT计算成本-效果比(CER)和增量成本-效果比(ICER)进行成本-效果和敏感性分析。统计学方法采用卡方检验。结果ITT中经验组、基因组、药敏组分别纳入200、126、168例患者,PP中3组分别纳入190、123、164例患者。ITT分析结果显示,经验组、基因组、药敏组的H.pylori根除率分别为80.5%(161/200)、94.4%(119/126)、95.2%(160/168),PP分析结果显示3组的H.pylori根除率分别为84.7%(161/190)、96.7%(119/123)、97.6%(160/164),差异均有统计学意义(χ^(2)=25.39、24.93,均P<0.001)。ITT和PP分析中基因组、药敏组的H.pylori根除率均高于经验组(χ^(2)=12.40、17.80、11.42、17.13,均P<0.001)。成本-效果分析显示,经验组、基因组、药敏组的治疗直接成本分别为400.8、729.2、779.2元,3组CER分别为4.98、7.72、8.18元/%。基因组、药敏组相较于经验组的ICER分别为23.6、25.7元/%。敏感性分析显示,当基因检测费用下调或上调20%,基因组相较于经验组的ICER分别为21.8、25.5元/%;当药敏试验费用下调或上调20%,药敏组�Objective To explore the efficacy of precise and empirical bismuth-containing quadruple therapy guided by clarithromycin sensitivity testing in the first eradication of Helicobacter pylori(H.pylori)in Ningxia.Methods From August 12,2022 to March 22,2023,600 patients diagnosed as H.pylori-positive by 14C-urea breath test(14C-UBT)for the first time in People′s Hospital of Ningxia Hui Autonomous Region,Ningnan Hospital of People′s Hospital of Ningxia Hui Autonomous Region,Zhongwei People′s Hospital,Yanchi County People′s Hospital,and Pingluo People′s Hospital were selected,and divided into empirical treatment group(hereinafter referred to as the empirical group),genetic testing group(hereinafter referred to as the genetic group),and drug sensitivity testing group(hereinafter referred to as the drug sensitivity group)by using random number table with 200 patients in each group.The empirical group did not undergo drug sensitivity testing and genetic testing,while the genetic and drug sensitivity groups were confirmed to be sensitive to clarithromycin through genetic testing and drug sensitivity testing,and the patients with drug-resistant were excluded,respectively.All the patients of the 3 groups received the same clarithromycin bismuth-containing quadruple therapy.Intention-to-treat(ITT)and per-protocol(PP)analyses were performed to compare the eradication rates of H.pylori among 3 groups.Cost-effectiveness ratio(CER)and incremental cost-effectiveness ratio(ICER)were used for cost-effectiveness and sensitivity analysis based on the ITT.Chi-square test was used for statistical analysis.Results There were 200,126,and 168 patients included in the empirical group,genetic group,and drug sensitivity group in ITT analysis,and 190,123,and 164 patients were enrolled in the 3 groups in PP analysis,respectively.The results of ITT analysis showed that the eradication rates of H.pylori in the empirical group,genetic group,and drug sensitivity group were 80.5%(161/200),94.4%(119/126),and 95.2%(160/168),respectively.The
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...